Pharmaceutical Industry
-
{
- All
- News
- Videos
-
Will Weight-Loss Drugs Hurt Fast Food And Alcohol Companies? Harsh Goenka Flags Industry Shift
Industrialist Harsh Goenka has highlighted the potential winners and losers, pointing to a major shift in consumer behaviour that businesses may need to prepare for.
-
India's Pharma Market Expands 10.7% On GLP-1 Launch: Zydus, Glenmark Lead Large-Cap Growth
A majority of companies within Nomura's coverage universe outpaced the broader pharma market in August. Zydus Lifesciences and Glenmark Pharmaceuticals posted the strongest YoY value expansion.
-
Jan Aushadhi Kendras Expand Across India From 84 In 2014 To More Than 19,200 In 2026
New Delhi, June 17 (IANS) From around 84 functional Jan Aushadhi Kendras in 2014, the network has grown to more than 19,200 Kendras across the country in 2026, making quality generic medicines accessible at affordable prices to millions of citizens, the government said on Wednesday.
-
Ozempic Revolution In India? Semaglutide Patent Expiry Sparks Generic Rush: Report
As the patent for semaglutide, the active ingredient in Ozempic, nears expiry, Indian pharmaceutical companies are preparing to launch cheaper generic versions.
-
Stock Markets Fluctuate In Narrow Range Ahead Of Budget Pesentation
From the 30 Sensex firms, Sun Pharma climbed nearly 3% post announcement of Q3 results, BEL, Power Grid, NTPC and HDFC Bank were among the other major gainers.
-
Lupin, Zydus Lifesciences Among DRChoksey’s Top Picks As Pharma Sector Braces For Q3 — Check Full List
Other notable picks include Alembic Pharma which is expected to benefit from specialty optionality and margin improvement.
-
Laurus Labs, Biocon, Rubicon Lead Motilal Oswal’s Top Picks As Q3 Healthcare Outlook Brightens — Check Details
Q3 Healthcare Results Preview: Motilal Oswal sees strong Q3 for Laurus Labs, Biocon; hospitals to drive sector momentum
-
Sun Pharma Arm Recalls Over 17k Units Of Antifungal Shampoo In US: USFDA
The company is recalling the affected lot due to 'Failed Impurity/Degradation specifications,' the USFDA stated.
-
Adani Enterprises, Airtel, HAL Shine Among Motilal Oswal's Top 10 Wealth Creators In Last Five Years
Adani Enterprises is among the top 10 Fastest Wealth Creators for a record five times in a row.
-
Stocks To Buy: Sun Pharma, Cipla, Rainbow Among Systematix Top Picks In Healthcare Space Post Q2 Results
Systematix’s top picks for the sector include Sun Pharma, Cipla, Ajanta Pharma among others - Check full list.
-
'Buy' Sun Pharma Shares Maintains Nirmal Bang Despite Minor EPS Cuts Due To Near-Term Headwinds
Despite near-term pressures from rising tax rates, operating costs, Nirmal Bang remains bullish on Sun Pharma’s long-term outlook.
-
M&M, Sun Pharma, Indian Hotels, Motherson Wiring, Ramco Cements, Aditya Birla Lifestyle & More Q2 Review
HDFC Securities recommends 'Add' rating for M&M, Motherson Sumi, TeamLease, 'Buy' call for Sun Pharma, Aditya Birla Lifestyle 'Reduce' rating to Indian Hotels, Kaynes, 'Sell' Ramco Cements- here's why
-
Sun Pharma Q2 Review: Systematix Maintains 'Buy' Post Inline Results — Check Target Price
Sun Pharma's India branded generics business recorded sales of Rs 47.3 billion, up 11% YoY and flat QoQ.
-
Q2 Results Updates: Aurobindo Pharma Profit Up, Britannia Bottom Line Jumps; Delhivery Slips Into Loss
Sun Pharma posted a marginal profit rise of 2.6% to Rs 3,118 crore.
-
Pharma Sector Sees Modest Growth Amid US Headwinds; Sun Pharma, Cipla Among ICICI Securities' Top Picks
Pharma Q2 Resulte Preview: ICICI Securities remains cautious on the near-term outlook for pharma sector citing US tariffs uncertainty, NLEM price revision in 2026.
-
Will Weight-Loss Drugs Hurt Fast Food And Alcohol Companies? Harsh Goenka Flags Industry Shift
Industrialist Harsh Goenka has highlighted the potential winners and losers, pointing to a major shift in consumer behaviour that businesses may need to prepare for.
-
India's Pharma Market Expands 10.7% On GLP-1 Launch: Zydus, Glenmark Lead Large-Cap Growth
A majority of companies within Nomura's coverage universe outpaced the broader pharma market in August. Zydus Lifesciences and Glenmark Pharmaceuticals posted the strongest YoY value expansion.
-
Jan Aushadhi Kendras Expand Across India From 84 In 2014 To More Than 19,200 In 2026
New Delhi, June 17 (IANS) From around 84 functional Jan Aushadhi Kendras in 2014, the network has grown to more than 19,200 Kendras across the country in 2026, making quality generic medicines accessible at affordable prices to millions of citizens, the government said on Wednesday.
-
Ozempic Revolution In India? Semaglutide Patent Expiry Sparks Generic Rush: Report
As the patent for semaglutide, the active ingredient in Ozempic, nears expiry, Indian pharmaceutical companies are preparing to launch cheaper generic versions.
-
Stock Markets Fluctuate In Narrow Range Ahead Of Budget Pesentation
From the 30 Sensex firms, Sun Pharma climbed nearly 3% post announcement of Q3 results, BEL, Power Grid, NTPC and HDFC Bank were among the other major gainers.
-
Lupin, Zydus Lifesciences Among DRChoksey’s Top Picks As Pharma Sector Braces For Q3 — Check Full List
Other notable picks include Alembic Pharma which is expected to benefit from specialty optionality and margin improvement.
-
Laurus Labs, Biocon, Rubicon Lead Motilal Oswal’s Top Picks As Q3 Healthcare Outlook Brightens — Check Details
Q3 Healthcare Results Preview: Motilal Oswal sees strong Q3 for Laurus Labs, Biocon; hospitals to drive sector momentum
-
Sun Pharma Arm Recalls Over 17k Units Of Antifungal Shampoo In US: USFDA
The company is recalling the affected lot due to 'Failed Impurity/Degradation specifications,' the USFDA stated.
-
Adani Enterprises, Airtel, HAL Shine Among Motilal Oswal's Top 10 Wealth Creators In Last Five Years
Adani Enterprises is among the top 10 Fastest Wealth Creators for a record five times in a row.
-
Stocks To Buy: Sun Pharma, Cipla, Rainbow Among Systematix Top Picks In Healthcare Space Post Q2 Results
Systematix’s top picks for the sector include Sun Pharma, Cipla, Ajanta Pharma among others - Check full list.
-
'Buy' Sun Pharma Shares Maintains Nirmal Bang Despite Minor EPS Cuts Due To Near-Term Headwinds
Despite near-term pressures from rising tax rates, operating costs, Nirmal Bang remains bullish on Sun Pharma’s long-term outlook.
-
M&M, Sun Pharma, Indian Hotels, Motherson Wiring, Ramco Cements, Aditya Birla Lifestyle & More Q2 Review
HDFC Securities recommends 'Add' rating for M&M, Motherson Sumi, TeamLease, 'Buy' call for Sun Pharma, Aditya Birla Lifestyle 'Reduce' rating to Indian Hotels, Kaynes, 'Sell' Ramco Cements- here's why
-
Sun Pharma Q2 Review: Systematix Maintains 'Buy' Post Inline Results — Check Target Price
Sun Pharma's India branded generics business recorded sales of Rs 47.3 billion, up 11% YoY and flat QoQ.
-
Q2 Results Updates: Aurobindo Pharma Profit Up, Britannia Bottom Line Jumps; Delhivery Slips Into Loss
Sun Pharma posted a marginal profit rise of 2.6% to Rs 3,118 crore.
-
Pharma Sector Sees Modest Growth Amid US Headwinds; Sun Pharma, Cipla Among ICICI Securities' Top Picks
Pharma Q2 Resulte Preview: ICICI Securities remains cautious on the near-term outlook for pharma sector citing US tariffs uncertainty, NLEM price revision in 2026.
